Comparable stake leader
ORBIMED ADVISORS LLC
SEC ownership of Corvus Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001626971.
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- CRVS on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ORBIMED ADVISORS LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ORBIMED ADVISORS LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001626971
- Issuer location
- South San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Corvus Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 10%
13D/G row: ORBIMED ADVISORS LLC
Showing 1-8 of 50 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
10%
Richard A. Miller MD
7.8%
Sirenia Capital Management LP
7.5%
BlackRock, Inc.
7.5%
ADAMS STREET PARTNERS LLC
3.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
13D/G
3/4/5
Company · Director, 10%+ Owner
|
10%
from 13D/G
|
$104,824,038
7,165,006 shares
|
— | 31 Mar 2026 |
| Richard A. Miller MD |
13D/G
3/4/5
Richard A. Miller · President and CEO, Director
|
7.8%
|
$40,653,959
6,085,922 shares
|
+$5,781,901 | 31 Dec 2025 |
| Sirenia Capital Management LP |
13D/G
|
7.5%
|
$101,657,601
6,831,828 shares
|
$0 | 31 Mar 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
7.5%
|
$94,497,846
6,325,157 shares
|
+$14,003,845 | 30 Jun 2026 |
| ADAMS STREET PARTNERS LLC |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
3.9%
from 13D/G
|
$47,922,262
3,275,616 shares
|
— | 31 Mar 2026 |
| STATE STREET CORP |
13F
Company
|
4.2%
|
$52,170,463
3,565,992 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.8%
|
$47,321,291
3,234,538 shares
|
— | 31 Mar 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
3.5%
|
$42,681,000
2,917,300 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$333,689.
Buys
$333,689
Insiders: 2
Sells
$0
Insiders: 0
Net
+$333,689
Shares: +28,632
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 28,632
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 28,632 | 0 | $333,689 | $0 | +$333,689 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to Corvus Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Peter A. Thompson
Net 12M change
+$333,689
Latest report
11 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Peter A. Thompson | Director, 10%+ Owner | $66,735,200 | Mixed | 11 Jun 2026 | ||
| Richard A. Miller MD | President and CEO, Director | $30,982,393 | +$83,453 | +0.27% | Mixed | 18 May 2026 |
| ORBIMED ADVISORS LLC | Director, 10%+ Owner | $29,796,393 | Filing P/S | 27 Jun 2025 | ||
| Terry P. Gould | Director, 10%+ Owner | $5,670,746 | Mixed | 13 Jun 2024 | ||
| ADAMS STREET PARTNERS LLC | 10%+ Owner | $2,587,737 | Mixed | 11 Aug 2022 | ||
| Ph.D. William Benton Jones | SVP, Pharmaceutical Development | $605,955 | Mixed | 04 Dec 2025 | ||
| David Scott Moore | Director | $250,235 | +$250,236 | +100% | Filing P/S | 11 Jun 2026 |
| EcoR1 Capital, LLC | 10%+ Owner | $64,051 | Mixed | 30 Sep 2021 | ||
| Andrew C. Chan | Director | Mixed | 23 Apr 2026 | |||
| Richard van den Broek | Director | Mixed | 11 Jun 2026 | |||
| Edith P. Mitchell | Director | Mixed | 06 Dec 2023 | |||
| Linda S. Grais | Director | Mixed | 11 Jun 2026 | |||
| Jeffrey Arcara | Chief Business Officer | Mixed | 04 Dec 2025 | |||
| Scott W. Morrison | Director | Mixed | 12 Jun 2025 | |||
| Leiv Lea | Chief Financial Officer | Mixed | 04 Dec 2025 | |||
| Clark Ian T. | Director | Mixed | 11 Jun 2026 |
Recent insider transactions for Corvus Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| David Scott Moore | CRVS | Common Stock | Purchase | $250,236 | $11.53 | 21,700 | 21,700 | 11 Jun 2026 | Direct | |
| David Scott Moore | CRVS | Stock Option (Right to Buy) | Award | 15,000 | 15,000 | 11 Jun 2026 | Direct | |||
| Ian T. Clark | CRVS | Stock Option (Right to Buy) | Award | 15,000 | 15,000 | 11 Jun 2026 | Direct | |||
| Linda S. Grais | CRVS | Stock Option (Right to Buy) | Award | 15,000 | 15,000 | 11 Jun 2026 | Direct | |||
| Peter A. Thompson | CRVS | Stock Option (Right to Buy) | Award | 15,000 | 15,000 | 11 Jun 2026 | Direct | |||
| Richard van den Broek | CRVS | Stock Option (Right to Buy) | Award | 15,000 | 15,000 | 11 Jun 2026 | Direct | |||
| Richard A. Miller MD | CRVS | Common Stock | Purchase | 0.58% | $83,453 | $12.04 | 6,932 | 1,195,035 | 18 May 2026 | By Trust |
| Andrew C. Chan | CRVS | Stock Option (Right to Buy) | Award | 30,000 | 30,000 | 23 Apr 2026 | Direct | |||
| Peter A. Thompson | CRVS | Common Stock | Options Exercise | 210,000 | 210,000 | 28 Jan 2026 | Direct | |||
| Peter A. Thompson | CRVS | Stock Option (Right to Buy) | Options Exercise | -100% | -210,000 | 0 | 28 Jan 2026 | Direct | ||
| Ph.D. William Benton Jones | CRVS | Stock Option (Right to Buy) | Award | 400,000 | 400,000 | 04 Dec 2025 | Direct | |||
| Richard A. Miller MD | CRVS | Stock Option (Right to Buy) | Award | 1,000,000 | 1,000,000 | 04 Dec 2025 | Direct | |||
| Jeffrey Arcara | CRVS | Stock Option (Right to Buy) | Award | 100,000 | 100,000 | 04 Dec 2025 | Direct | |||
| Leiv Lea | CRVS | Stock Option (Right to Buy) | Award | 400,000 | 400,000 | 04 Dec 2025 | Direct | |||
| David Scott Moore | CRVS | Stock Option (Right to Buy) | Award | 30,000 | 30,000 | 02 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.